OBI Pharma Asset Resilience Ratio

Latest as of June 2026: 6.83%

OBI Pharma asset resilience ratio. OBI Pharma (4174) has an Asset Resilience Ratio of 6.83% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4174 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$183.70 Million

≈ $5.79 Million USD Cash + Short-term Investments

Total Assets

NT$2.69 Billion

≈ $84.75 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of OBI Pharma (2011–2025)

Asset resilience ratio of OBI Pharma from 2011 to 2025. This chart shows how OBI Pharma's Asset Resilience Ratio has changed over time. Read OBI Pharma balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down OBI Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of OBI Pharma.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$183.70 Million	6.83%
Total Liquid Assets	NT$183.70 Million	6.83%

Asset Resilience Insights

Limited Liquidity: OBI Pharma maintains only 6.83% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

OBI Pharma Industry Peers by Asset Resilience Ratio

Compare OBI Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

OBI Pharma Asset Resilience Ratio by Year (2011–2025)

OBI Pharma asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for OBI Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.48%	NT$427.00 Million ≈ $13.45 Million	NT$3.42 Billion ≈ $107.79 Million	-12.26pp
2024-12-31	24.74%	NT$1.40 Billion ≈ $44.07 Million	NT$5.65 Billion ≈ $178.12 Million	-8.86pp
2023-12-31	33.60%	NT$1.88 Billion ≈ $59.33 Million	NT$5.60 Billion ≈ $176.55 Million	+33.13pp
2022-12-31	0.47%	NT$31.46 Million ≈ $991.23K	NT$6.63 Billion ≈ $209.00 Million	-2.69pp
2021-12-31	3.16%	NT$141.77 Million ≈ $4.47 Million	NT$4.49 Billion ≈ $141.36 Million	-4.02pp
2020-12-31	7.18%	NT$383.53 Million ≈ $12.08 Million	NT$5.34 Billion ≈ $168.23 Million	+7.16pp
2019-12-31	0.02%	NT$1.39 Million ≈ $43.92K	NT$5.66 Billion ≈ $178.42 Million	-38.95pp
2017-12-31	38.97%	NT$2.02 Billion ≈ $63.72 Million	NT$5.19 Billion ≈ $163.51 Million	+1.68pp
2016-12-31	37.29%	NT$2.36 Billion ≈ $74.34 Million	NT$6.33 Billion ≈ $199.37 Million	+4.71pp
2012-12-31	32.58%	NT$284.81 Million ≈ $8.97 Million	NT$874.17 Million ≈ $27.54 Million	-41.39pp
2011-12-31	73.97%	NT$386.65 Million ≈ $12.18 Million	NT$522.72 Million ≈ $16.47 Million	--

pp = percentage points

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$191.11 Million

NT$6.07 Billion TWD

Market Cap Rank

#16530 Global

#799 in Taiwan

Share Price

NT$46.10

Change (1 day)

-2.54%

52-Week Range

NT$23.25 - NT$59.90

All Time High

NT$743.00